{
  "relevance": {
    "rules": [
      {
        "rule_id": "relevance_rule_1",
        "rule_text": "Abstracts are relevant if they mention any client keyword related to the IgA nephropathy (IgAN) disease area.",
        "processing_type": "keyword_filtering",
        "reasoning": "Relevance is defined by the presence of any keyword from the client's list, as all provided keywords fall under the specified disease area of interest, IgA nephropathy (IgAN).",
        "include_logic": {
          "any_of": [
            {
              "categories": [
                "Clinical Trial",
                "Company",
                "Disease",
                "Endpoints",
                "Other",
                "Treatment",
                "Treatment Class"
              ],
              "field": "keywords",
              "values": [
                "PROTECT",
                "ALIGN",
                "ORIGIN 3",
                "RUBY-3",
                "NCT05799287",
                "VISONARY",
                "APPLAUSE",
                "Novartis",
                "Roche",
                "Travere Therapeutics",
                "Otsuka",
                "Vera Therapeutics",
                "Alpine Immune Sciences",
                "Vertex Pharmaceuticals",
                "Remegen",
                "IgA Nephropathy",
                "Proteinuria; OR UPCR",
                "UACR",
                "eGFR",
                "KDIGO",
                "Remission",
                "Disease modification",
                "IgA-IgG immune complexes",
                "Subgroup",
                "immunosuppression",
                "non-immunosuppression",
                "pathogenic Mechanisms",
                "B cell depletion +/- B cell activation +/- B cell targeting",
                "MEST-C",
                "treatment options",
                "Clinical Trial Endpoints",
                "Biomarkers",
                "Complement proteins +/- C3 Complement +/- C4 Complement",
                "Standard of care",
                "targeted-release formulation budesonide",
                "Telitacicept",
                "Sparsentan",
                "Iptacopan",
                "Atrasentan",
                "Zigakibart",
                "Povetacicept",
                "Sibeprenlimab",
                "Atacicept",
                "Methylprednisone +/- methylprednisolone",
                "BAFF +/- APRIL; OR APRIL alone; OR BAFF/April; OR Blys/April; OR APRIL/BLyS",
                "AT1/EDNRA antagonist? +/- ERA +/- endothelian receptor antagonist",
                "Complement Factor B inhibitor +/- alternative pathway +/- complement inhibition +/- complement system inhibitors",
                "ENDR Antagonist",
                "Systemic steroid +/- Systemic glucocorticoid +/- Systemic corticosteroid",
                "SGLT2 +/- inhibition",
                "optimized supportive care +/- ACE/ARB +/- RASi +/- RAASi",
                "Gd-IgA OR IgA1 OR Gd-IgA1 OR Galactose deficient",
                "Chinook Therapeutics",
                "Immune Complex",
                "budesonide",
                "prednisone",
                "TRF budesonide",
                "Veloxis",
                "Asahi Kasei",
                "Tarpeyo",
                "Kinpeygo"
              ]
            }
          ]
        },
        "exclude_logic": ""
      }
    ]
  },
  "priorities": {
    "Very High": {
      "rules": [
        {
          "rule_id": "very_high_rule_1",
          "rule_text": "Assigned by the Calliditas team.",
          "processing_type": "none",
          "reasoning": "The rule states that this priority is assigned manually by the client team, which cannot be automated.",
          "include_logic": {},
          "exclude_logic": ""
        }
      ]
    },
    "High": {
      "rules": [
        {
          "rule_id": "high_rule_1",
          "rule_text": "Relevant abstracts that include Phase 2/3 data, meta-analyses, or real-world data (including patient reported outcomes, retrospective analyses, and registry data).",
          "processing_type": "context_filtering",
          "reasoning": "This rule prioritizes abstracts based on study type and data source (Phase 2/3, RWD, PROs), which requires searching for contextual terms beyond the client's keyword list.",
          "include_logic": {
            "any_of": [
              {
                "categories": [
                  "Study Type/Data Source"
                ],
                "field": "keywords",
                "values": [
                  "Phase 2",
                  "Phase II",
                  "Phase 3",
                  "Phase III",
                  "meta-analysis",
                  "meta-analyses",
                  "real-world data",
                  "RWD",
                  "real-world evidence",
                  "RWE",
                  "patient reported outcome",
                  "patient reported outcomes",
                  "PRO",
                  "retrospective",
                  "registry data",
                  "registry"
                ]
              }
            ]
          },
          "exclude_logic": ""
        }
      ]
    },
    "Internal": {
      "rules": [
        {
          "rule_id": "internal_rule_1",
          "rule_text": "Abstracts from Calliditas sponsored studies.",
          "processing_type": "keyword_filtering",
          "reasoning": "This rule prioritizes abstracts sponsored by 'Calliditas'. This is translated into a keyword search for the company name, which was not on the provided keyword list but is explicitly mentioned in the rule.",
          "include_logic": {
            "any_of": [
              {
                "categories": [
                  "Company"
                ],
                "field": "keywords",
                "values": [
                  "Calliditas"
                ]
              }
            ]
          },
          "exclude_logic": ""
        }
      ]
    },
    "Medium": {
      "rules": [
        {
          "rule_id": "medium_rule_1",
          "rule_text": "Relevant abstracts that include Phase 1 data, general HEOR studies, prognostic studies, or preclinical studies.",
          "processing_type": "context_filtering",
          "reasoning": "This rule prioritizes abstracts based on study type (Phase 1, HEOR, prognostic, preclinical), which requires searching for contextual terms not on the client's keyword list. The term 'other general studies' is too vague to be automated.",
          "include_logic": {
            "any_of": [
              {
                "categories": [
                  "Study Type/Data Source"
                ],
                "field": "keywords",
                "values": [
                  "Phase 1",
                  "Phase I",
                  "HEOR",
                  "health economics",
                  "outcomes research",
                  "prognostic",
                  "preclinical"
                ]
              }
            ]
          },
          "exclude_logic": ""
        }
      ]
    },
    "Low": {
      "rules": [
        {
          "rule_id": "low_rule_1",
          "rule_text": "All relevant abstracts that do not meet the criteria for a higher priority level.",
          "processing_type": "none",
          "reasoning": "This is a default or fall-through priority. Any abstract deemed relevant that does not meet the criteria for Very High, High, Internal, or Medium priority will be assigned Low priority. This logic is handled by the system's hierarchical processing, not by a specific keyword rule.",
          "include_logic": {},
          "exclude_logic": ""
        }
      ]
    }
  }
}